certepetide — Full data
2026
Additional data from Cohorts A and B was presented at the ESMO annual meeting in October 2025 with a final study report of the ASCEND study anticipated to be made available in 2026.Source filing
LSTA biotech catalysts & pipeline
LISATA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
MAR001 — Topline data
2027
This transaction provides the combined company with the resources to advance our two clinical stage drug candidates through pivotal milestones, including MAR001 topline Phase 2b data in severe hypertriglyceridemia and MAR002 Phase 2 proof of concept data in patients with acromegaly next year, as well as initiation of Phase 3 registrational studies for both programsSource filing
MAR002 — Initial data
2027
This transaction provides the combined company with the resources to advance our two clinical stage drug candidates through pivotal milestones, including MAR001 topline Phase 2b data in severe hypertriglyceridemia and MAR002 Phase 2 proof of concept data in patients with acromegaly next year, as well as initiation of Phase 3 registrational studies for both programsSource filing
MAR001/005 — Topline data
Q4 2027
Both studies are expected to report topline data in the fourth quarter of 2027.Source filing
MAR002 — Topline data
Q4 2027
Both studies are expected to report topline data in the fourth quarter of 2027.Source filing
MAR001 — Conference presentation
Nov 9
Date/Time: Monday, November 9, 2026, 8:00 a.m. CTSource filing